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Putative Transcriptomic Biomarkers in the Inflammatory
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Disorder Patients from Control Subjects and Bipolar
Disorder Patients
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Abstract
Mood disorders consist of two etiologically related, but distinctly treated illnesses, major depressive disorder (MDD) and
bipolar disorder (BPD). These disorders share similarities in their clinical presentation, and thus show high rates of
misdiagnosis. Recent research has revealed significant transcriptional differences within the inflammatory cytokine pathway
between MDD patients and controls, and between BPD patients and controls, suggesting this pathway may possess
important biomarker properties. This exploratory study attempts to identify disorder-specific transcriptional biomarkers
within the inflammatory cytokine pathway, which can distinguish between control subjects, MDD patients and BPD
patients. This is achieved using RNA extracted from subject blood and applying synthesized complementary DNA to
quantitative PCR arrays containing primers for 87 inflammation-related genes. Initially, we use ANOVA to test for
transcriptional differences in a ‘discovery cohort’ (total n = 90) and then we use t-tests to assess the reliability of any
identified transcriptional differences in a ‘validation cohort’ (total n = 35). The two most robust and reliable biomarkers
identified across both the discovery and validation cohort were Chemokine (C-C motif) ligand 24 (CCL24) which was
consistently transcribed higher amongst MDD patients relative to controls and BPD patients, and C-C chemokine receptor
type 6 (CCR6) which was consistently more lowly transcribed amongst MDD patients relative to controls. Results detailed
here provide preliminary evidence that transcriptional measures within inflammation-related genes might be useful in
aiding clinical diagnostic decision-making processes. Future research should aim to replicate findings detailed in this
exploratory study in a larger medication-free sample and examine whether identified biomarkers could be used
prospectively to aid clinical diagnosis.
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Introduction
The term ‘mood disorder’ refers to a category of psychiatric
illness that is characterized by a pathological distortion of affect
[1]. Mood disorders represent the most common form of severe
adult-onset psychiatric disorder and are predicted to be the second
most common cause of morbidity by 2020 [2,3]. They consist of
two etiologically related [4] but distinctly treated psychiatric
illnesses [5], major depressive disorder (MDD) and bipolar
disorder (BPD). Both MDD and BPD are clinically characterized
by episodes of depression (e.g. lowered mood, loss of interest or
pleasure, loss of energy); with BPD also consisting of episodes of
mania or hypomania (e.g. expanded self-esteem, increased
distractibility, talkativeness) [6,7].
Despite the establishment of clinical diagnostic criteria for
MDD and BPD, the heterogeneous nature of these disorders, the
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similarities they share in their clinical presentation, and the
absence of specific biomarkers, means there are relatively high
rates of misdiagnosis [8,9]. BPD is often misdiagnosed in the first
instance [10], and an estimated 5.7 years on average is required
for the correct diagnosis [11]. Most frequently, BPD is misdiag-
nosed as MDD due to their overlapping symptomology, the often
later onset of mania, and more frequent occurrence of depressive
episodes in BPD patients [12,13]. Misdiagnosis may be particu-
larly high when BPD patients present symptoms indicative of a
clinically significant depressive episode but are premorbid for
manic symptoms, or have failed to recognize previous manic
states. Misdiagnosis, and therefore incorrect treatment of BPD
with monotherapy antidepressant treatment, increases the risk of
antidepressant induced mania [14,15] and ‘‘cycle acceleration’’
(an increased frequency of episodes) [13]; both of which can have
damaging effects on disease prognosis. Consequently, the estab-
lishment of biomarkers specific to each disorder remains a key
goal, so that the correct diagnosis and treatment can be obtained
for a patient from the outset.
The clear need for an objective, empirical method of diagnosis
has led to genome-wide association studies (GWASs) attempting to
identify genes associated with MDD and BPD. However, despite
twin studies suggesting mood disorders are moderately heritable,
GWASs have largely been unsuccessful in identifying genes
robustly associated with MDD [4,16], with only recent reports
from very large-scale studies finding genes potentially being
associated with BPD [17]. In addition to genetic background, it
has been established that environmental factors, such as stressful
life events, can also increase a person’s susceptibility to developing
a mood disorder, and precipitate mood disorder episodes [18,19].
Subsequently, it has been proposed that a lack of findings from
GWASs might relate to the more salient presence of gene-
environment interactions [20], as supported by studies in the field
[21–24]. Therefore, it may be the interface between genes and
environment that contains the most valuable biomarker informa-
tion about mood disorders, as opposed to genotype alone. Thus,
focusing efforts on identifying biomarkers at the level of the
transcriptome, which represents a functional molecular output of
gene-environment interactions, might yield more fruitful results.
Cytokines are a group of cell-signaling proteins which, in the
periphery, aid inflammatory processes and the immune system to
form coordinated responses to infection [25]. Cytokines are also
expressed centrally and have effects on the brain, influencing
neurotransmitter systems, neuroendocrine function and neural
plasticity, and converging evidence suggests they may play an
important role in the pathophysiology of mood disorders [26].
Furthermore, cytokines can cross the blood-brain barrier [27], so
peripheral cytokines may represent a potentially useful biomarker
resource relating to mood disorders. Indeed, both protein and
transcriptomic studies performed in blood have revealed differ-
ences in the expression of cytokines such as interleukin-6, tumor
necrosis factor and interleukin-1b amongst MDD patients relative
to controls [25,28–32]. Similarly, the transcription of cytokines has
been found to differentiate between BPD patients and controls
[33]. However, no studies have yet investigated whether disorder-
specific transcriptional differences exist within the inflammatory
cytokine pathway, which might be used as clinical diagnostic aids
to differentiate between MDD and BPD patients.
The current study aims to identify transcriptomic biomarkers in
the inflammatory cytokine pathway which could be used to
distinguish between controls subjects, MDD patients and BPD
patients. We achieve this using RNA extracted from whole blood
and examine an extensive set of inflammatory-related transcripts
including genes coding for: interleukins and interleukin receptors,
chemokines and chemokine receptors, the tumor necrosis factor
cytokine family and receptors, and other inflammatory regulators.
We initially test for differences in a discovery cohort (total n = 90),
and then attempt to replicate any findings from our discovery
cohort in a validation cohort (total n = 35).
Methods
Clinical samples
Patient samples used in this study were collected from two
methodologically similar studies, the Bipolar Association Case–
Control Study (BACCS) [34] and the Genome-based Therapeutic
Drugs for Depression Project (GENDEP) [35].
(i) Bipolar Disorder Patients. BPD patients in BACCS
were recruited from three sites, Toronto Canada, London UK and
Dundee UK. BACCS was a community-based study, where
subjects were recruited from psychiatric clinics, hospitals, primary
care physicians and patient support groups. BPD patients were
included in the study if they were over the age of 18 and had been
diagnosed with Bipolar I or Bipolar II disorder as defined by the
DSM-IV or ICD-10 [6,7]. All patients were interviewed using the
Schedules for Clinical Assessment in Neuropsychiatry (SCAN)
[36]. All patients recruited in BACCS were euthymic (not in a
clinically significant mood episode) at the time of interview and
blood collection. All subjects were of White European parentage.
Exclusion criteria include: first-degree relative having fulfilled
criteria for schizophrenia; psychotic symptoms that were mood
incongruent or present when there was no evidence for mood
disturbance; intravenous drug use with a lifetime diagnosis of drug
dependency; mania or depression occurring solely in relation to, or
a consequence of, alcohol or substance abuse/dependence and/or
medical illness; being related to an individual already included in
the study.
The current study utilized 40 BPD patient samples in total (30
in the discovery cohort and 10 in the validation cohort) collected
only from the Dundee UK site, as this was the only site to collect
blood for transcriptomic experiments. The subset used here was
randomly selected from a larger group of samples. Further patient
characteristics are detailed in Tables 1 and 2, note that information
on comorbidities and current medication use is based on self-
reports at the time of blood collection.
(ii) Major Depressive Disorder Patients. MDD patient
samples were collected as part of the European study GENDEP,
which is a 12-week partially randomized open label pharmaco-
genetic study. Patients were selected if they were diagnosed with
MDD of at least moderate severity according to ICD-10 or DSM-
IV criteria [6,7]. Patients in GENDEP were aged between 19–72
years and of White European parentage. Diagnoses were
established using the semistructured SCAN interview [36].
Exclusion criteria included personal and family history of
schizophrenia or bipolar disorder; current substance dependence;
being related to an individual already included in the study; known
treatment resistance to both of the antidepressants given as part of
the study.
The current study utilizes 45 patient samples in total (30 in the
discovery cohort and 15 in the validation cohort), which were
randomly selected from the larger GENDEP sample set. Blood
samples were collected both at the start of GENDEP and after
eight weeks of treatment with escitalopram as described previously
[37]. All patients completed the Beck Depression Inventory at the
time of blood collection (BDI) [38]. We utilized blood collected
after eight weeks of treatment with escitalopram, for both our
discovery and validation cohorts. We chose this time point as it
allowed us to adjust for the possible dynamic effects of current
Disorder-Specific Biomarkers for Mood Disorders
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mood state on gene transcription, and so allowing us to accurately
compare our MDD sample with our euthymic BPD patients and
control subject sample. Unlike at the start of the GENDEP trial
where all patient were in a clinically significant depressed state,
after eight weeks of treatment, 26 patients still showed mild to
moderate depression (defined here by BDI.10), whereas 19
patients were no longer in a clinically significant depressed state
(defined here by BDI#10). Furthermore, our previous work has
revealed that escitalopram has no significant effect on the
transcription of genes in the inflammatory cytokine pathway with
the exception of ATP-binding cassette sub-family F member 1
(ABCF1) [39], which has been excluded as a potential biomarker.
Subsequently, medication is unlikely to act as a confounding factor
in this MDD sample. Further patient characteristics are shown in
Tables 1 and 2, note that information on comorbidities and current
medication use is based on self-reports at the time of blood
collection.
We also utilized blood which was collected at the start of
GENDEP to ascertain how stable transcriptional biomarkers were
at differentiating MDD patients from other subject groups. At the
start of GENDEP all patients had been drug-free for two weeks
and were all in a clinically significant mood state (BDI.10). We
Table 1. A summary of subject characteristics in our discovery cohort.
Subject Characteristic BPD MDD Control Total Sample
Sample number 30 30 30 90
Age (mean, (SD))* 53.10 (14.17) 41.23 (12.53) 52.40 (14.35) 48.91 (14.62)
Males (n) 10 10 9 29
Females (n) 20 20 21 61
BMI (mean, (SD)) 26.66 (5.51) 25.90 (4.11) 24.93 (3.33) 25.83
Cardiovascular Problem (n)* 8 1 5 14
Diabetes (n) 2 0 2 4
Antidepressants (n) 6 30 0 36
Lithium (n) 20 0 0 20
Carbamazepine (n) 3 0 0 3
Sodium valproate (n) 3 0 0 3
Antipsychotics (n) 16 0 0 16
This includes general characteristics (total number in each subject group, age, number of males, number of females), information about co-morbidity (body mass index
(BMI), number with diabetes, number with cardiovascular problems), and current medication use (antidepressants, antipsychotics, lithium, carbamazepine, and sodium
valproate). Note: cardiovascular problems is an umbrella term consisting of those subjects who reported high levels of cholesterol, high blood pressure, or a history of
angina or heart attacks. For age, males (n), females (n), BMI, cardiovascular problems (n), and diabetes (n) we performed ANOVA to assess differences between groups.
Significant differences between groups (p#0.05) is indicated with a *. [Age: F(2, 87) = 7.077, p = 0.001; Cardiovascular Problems: F(2, 87) = 3.252, p = 0.043].
doi:10.1371/journal.pone.0091076.t001
Table 2. A summary of subject characteristics in our validation cohort.
Subject
Characteristic BPD MDD Control Total Sample
Sample number 10 15 10 35
Age (mean, (SD)) 52.50 (13.10) 45.19 (12.14) 54.6 (12.33) 49.83 (12.84)
Males (n) 2 7 3 12
Females (n) 8 8 7 23
BMI (mean, (SD)) 24.68 (3.92) 26.01 (2.75) 28.33 (4.46) 26.22 (12.84)
Cardiovascular
Problem (n)
3 4 0 7
Diabetes (n) 2 0 0 2
Antidepressants (n) 1 0 0 1
Lithium (n) 7 0 0 7
Carbamazepine (n) 2 0 0 2
Sodium valproate (n) 1 0 0 1
Antipsychotics (n) 3 0 0 3
This includes general characteristics (total number in each subject group, age, number of males, number of females), information about co-morbidity (body mass index
(BMI), number with diabetes, number with cardiovascular problems), and current medication use (antidepressants, antipsychotics, lithium, carbamazepine, and sodium
valproate). Note: cardiovascular problems is an umbrella term consisting of those subjects who reported high levels of cholesterol, high blood pressure, or a history of
angina or heart attacks. For age, males (n), females (n), BMI, cardiovascular problems (n), and diabetes (n) we performed ANOVA to assess differences between groups.
Significant differences between groups (p#0.05) is indicated with a *.
doi:10.1371/journal.pone.0091076.t002
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assess whether transcripts identified in the discovery cohort and
replicated in the validation cohort, continue to differentiate MDD
patients from other subject groups when blood is collected at a
different time point, during a different mood state, and during the
absence of medication.
(iii) Control Subjects. Control subjects were selected from
BACCS where they were screened for lifetime absence of
psychiatric disorders using a modified version of the Past History
Schedule [40]. All controls subjects were of White European
parentage. Exclusion criteria were if they; or a first-degree relative,
ever fulfilled criteria for BPD, MDD or any other psychiatric
disorder; if they had a BDI score of greater than 10 [38]; did not
return consent; failed to return cheek swabs or successfully give
blood. The current study utilized 40 subject blood samples in total
(30 in discovery cohort and 10 in the validation cohort), collected
only from the Dundee UK site, as this was the only site to collect
blood for transcriptomic experiments. Further subject character-
istics are shown in Tables 1 and 2, note that information on
comorbidities and current medication use is based on self-reports
at the time of blood collection.
Ethics statement
The BACC and GENDEP studies were approved by The Joint
South London and Maudsley NHS Trust Institute of Psychiatry
Research Ethics Committee and at each participating centre and
all subjects provided written informed consent.
Experimental details
All blood samples from BACCS and GENDEP were collected
in 10 ml PAXgene tubes (PreAnalytiX, Switzerland) and stored at
280uC. Prior to the start of gene expression studies, PAXgene
tubes were allowed to thaw for 12 hours at room temperature.
RNA extraction was performed using the Qiagen PAXgene Blood
miRNA Kit (PreAnalytiX) following the standard manufacturer’s
protocol. The purity and quantity of RNA was measured using the
Nanodrop, ND1000 (Thermoscientific, Wilmington, DE). All
samples had 260/280 ratios of between 1.9 and 2.3. RNA
integrity numbers (RINs) were furthermore assessed using the
Agilent 2100 Bioanalyzer (Agilent Technologies, Berkshire, UK)
and the average RIN was 861.5.
Reagents used in the quantitative PCR (qPCR) component of
the study were manufactured by SABiosciences (Frederick, MD,
USA). Complementary DNA (cDNA) was prepared using 1 mg of
total RNA and the SABiosciences RT2 HT First Strand Kit
following the manufacturer’s protocol. Briefly, following genomic
DNA removal, the samples were incubated for 15 minutes at 42uC
with 6 ml of BC4 RT Mastermix (SABiosciences). The reverse
transcriptase enzyme was subsequently inactivated at 95uC for 5
minutes. cDNA samples generated were stored at 220uC prior to
use in the qPCR experiments.
Customized 384-well arrays were designed for qPCR experi-
ments. These arrays contained lyophilized primers for the 84 genes
listed in the commercially available Human Inflammatory
Cytokines & Receptors PCR Array (SABiosciences), with the
addition of gene primers for interleukin 11 (IL11), interleukin-6
(IL6) and the glucocorticoid receptor (NR3C1). Each array
contained five housekeeping genes for normalization. These
include: b2-microglobulin (B2M), hypoxanthine phosphoribosyl-
transferase (HPRT1), ribosomal protein L13a (RPL13A), glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) and b-actin (ACTB).
The three most stable housekeeping genes were selected based on
RefFinder analyses and used for normalization across samples.
Each 384-well array was designed to analyze four samples
simultaneously. The qPCR reagents used consisted of: 550 ml of
2X SABiosciences RT2 qPCR Master Mix (SYBR green), 102 ml
of diluted synthesized cDNA and 448 ml RNAse free water, with a
total volume of 1100 ml for each sample. Each qPCR array
contained the following controls: human genomic DNA control
(gDNA), reverse transcription control (RTC) and a positive PCR
control (PPC). To ascertain whether samples passed quality
control checks for gDNA and RTC, the manufacturer’s quality
control criteria were applied. The qPCR reactions were performed
using the ABI Prism 7900HT Sequence Detection System
(Applied Biosystems, California, USA). Thermal cycling condi-
tions consisted of an enzyme activation stage (95uC for 10
minutes), followed by 40 cycles of a denaturation stage (95uC for
15 secs) and a hybridization and extension stage (65uC for 1
minute). The software program SDS 2.3 (Applied Biosystems)
generated cycle threshold values (Ct) from the data collected, see
Table S1 for raw Ct values.
Statistical Analysis
Ct values of greater than 37 were removed and excluded from
further analysis as such high Ct values are indicative of very low
expression levels. Furthermore, if as a result of data removal, a
transcript showed missing data for more than half of the total
patient sample, that transcript was excluded from further analysis.
The relative expression of target genes was calculated by
subtracting the mean Ct of the selected reference genes from the
Ct of the target gene to generate DCt values [41]. As mood
disorder pharmacotherapies can affect housekeeping gene expres-
sion, the three most stable housekeeping genes were selected as
reference genes for normalization purposes based on RefFinder
analyses (http://www.leonxie.com/referencegene.php) [42]. Rel-
ative expression values were then adjusted for PPC (to account for
any inter-plate variability), age, sex, current mood status and the
presence of comorbid disorders (diabetes, cardiovascular prob-
lems). Adjusted DCt were used in statistical calculations and
adjusted 22DCt were used to generate plots [41].
To ascertain whether significant transcriptional differences
existed between control, MDD and BPD subject groups in our
discovery cohort, we performed analysis of variance (ANOVA)
tests. Partial eta squared (gp
2) was calculated as an estimate of
effect size, by dividing the sum of squares between groups by the
total sum of squares. Games-Howell post-hoc tests were subse-
quently performed to correct for multiple testing and to generate
pair-wise comparisons between subject groups [43]. When making
pairwise comparisons, Cohen’s d was generated as our estimate of
effect size, by calculating the mean differences between our two
subject groups, and dividing this result by the square root of the
within-groups mean square. Small (d<0.2), medium (d<0.5) and
large effect sizes (d$0.8) were then assumed, as according to
Cohen [44]. Based on results from the discovery cohort, we then
performed one-tailed independent sample t-tests in an attempt to
replicate findings in our validation cohort. Similarly, Cohen’s d
was generated as our estimate of effect size by multiplying the t-test
statistic value by two and dividing the result by the square root of
the degrees of freedom [44].
We have previously shown that escitalopram does not affect the
transcription of inflammatory cytokines in our MDD patient
sample, with the exception of ABCF1, which has been excluded as
a potential biomarker [39]. However, medications used in our
BPD patient sample may affect transcription, and as such we
performed post-hoc analyses to assess whether these medications
may represent confounding factors. Consequently, for each gene’s
expression that significantly differentiated our BPD subjects from
either controls or MDD patients, we ran univariate linear
regressions for our BPD sample only. The expression of the
Disorder-Specific Biomarkers for Mood Disorders
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significant gene was selected as the dependent variable and
regularly used medications included as covariates. For any
medications which significantly predicted the expression of a gene
(p#0.05), we excluded that transcript as a likely biomarker.
For any transcripts that significantly differentiated MDD
patients from control subjects or BPD patients, in both the
discovery and validation cohorts, we performed an additional test
to determine the stability of these transcripts as state biomarkers
for MDD. We achieved this by utilizing transcript data generated
from blood collected at a different time point (start of GENDEP),
under different conditions (patients were drug free, all patients
were in a depressed episode). As before, we attempted to validate
biomarkers by performing one-tail independent samples t-tests.
All statistical analyses were performed using SPSS Version 15
(SPSS Inc., Chicago, Illinois, USA). Graphs were generated using
the ‘plot’ function in R (http://www.R-project.org).
Results
Validation of internal controls
All qPCR plates passed quality control checks outlined. 71 out
of 87 target genes were sufficiently detectable according to out set
criteria. RefFinder analyses revealed that B2M, RPL13A and
ACTB were the three most stable housekeeping genes across all
samples and subsequently were selected for normalization
purposes, see Figure S1. Adjusted relative expression for all subjects
can be found in Table S2.
Transcriptional differences between subject groups
(i) Discovery Cohort. ANOVA revealed 11 genes which
showed nominally significant transcriptional differences (p#0.05)
between our three subject groups. The most significant differences
between subject groups were found in Chemokine (C-C motif)
ligand 24 [CCL24: F (2, 85) = 6.438, p = 0.002, gp
2 = 0.134] and
interleukin-8 [IL8: F (2, 87) = 6.872, p = 0.002, gp
2 = 0.136], see
Table S3 for full ANOVA results. Games-Howell post hoc analyses
were subsequently performed on all genes present on the array.
These tests correct for the effects of multiple testing, and generate
pairwise comparisons, see Table S4 for full results. Table 3 lists the
genes which produced significant p-values from the ANOVA
analyses (p#0.05) and details corrected pair-wise results generated
from Games-Howell post hoc analyses. None of the medications
used by our BPD patients significantly affected the transcription of
any of the potential biomarkers identified in our discovery cohort.
(ii) Validation. One-tailed independent t-tests were used in
our validation cohort to test whether we could replicate potential
biomarkers identified from our discovery cohort, see Table 4.
Higher transcription of CCL24, the most significant difference
revealed between subjects in our discovery cohort, again
significantly differentiated MDD patients from controls
(t = 2.394, d.f. = 23, p = 0.0125, d= 0.998) and BPD patients
(t = 2.674, d.f. = 23, p = 0.007, d= 1.115) in the validation cohort,
see Figure 1. Lowered transcription of CCR6 also continued to
differentiate MDD patients from controls in our validation cohort
(t =22.315, d.f. = 23, p = 0.015, d= 0.965), see Figure 2.
We additionally used one-tailed independent samples t-tests to
observe whether CCL24 and CCR6 transcription continued to
differentiate MDD patients from our other subject groups when
blood was collected from a different time point (patients all in a
current episode and drug-free). Again, we found that higher
transcription of CCL24 significantly differentiated MDD patients
from controls in our discovery cohort (t = 7.237, d.f. = 57,
p#0.000001, d= 1.917) and validation cohort (t = 6.603,
d.f. = 23, p#0.000001, d= 2.754) when MDD blood was collected
from a different time point. Similarly, we found that higher
transcription of CCL24 significantly differentiated MDD patients
from BPD patients in both our discovery cohort (t = 7.247,
d.f. = 57, p#0.000001, d= 1.920) and validation cohort (t = 4.511,
d.f. = 11.64, p#0.001, d= 2.644). Additionally, lower transcription
of CCR6 continued to differentiate MDD patients from controls in
both our discovery cohort (t =21.841, d.f. = 58, p = 0.035,
d= 0.483) and validation cohort (t =21.799, d.f. = 23, p = 0.043,
d= 0.750).
Table 3. A table detailing corrected Games-Howell pair-wise post-hoc analysis results for genes which produced significant p-
values (p#0.05) in ANOVA from our discovery cohort.
Discovery Cohort
MDD v Control MDD v BPD BPD v Controls
Gene
Mean
Difference S.E.
p-
value 95% C.I. d
Mean
Difference S.E.
p-
value 95% C.I. d
Mean
Difference S.E.
p-
value 95% C.I. d
CCL24 20.779 0.259 0.011 21.404 20.153 0.867 20.676 0.249 0.025 21.280 20.072 0.753 20.102 0.181 0.839 20.538 0.334 0.114
CCR4 0.615 0.255 0.049 0.001 1.229 0.619 0.507 0.278 0.170 20.161 1.175 0.511 0.108 0.236 0.891 20.460 0.676 0.109
CCR6 0.510 0.192 0.028 0.047 0.973 0.815 0.091 0.215 0.907 20.426 0.607 0.115 0.419 0.205 0.111 20.074 0.913 0.530
CCR9 0.644 0.249 0.032 0.046 1.242 0.665 0.276 0.247 0.507 20.318 0.870 0.285 0.368 0.256 0.327 20.247 0.983 0.380
CXCL1 0.738 0.261 0.017 0.111 1.366 0.705 0.353 0.276 0.413 20.311 1.017 0.337 0.385 0.274 0.345 20.274 1.045 0.368
CXCL6 1.007 0.347 0.015 0.167 1.848 0.763 0.549 0.377 0.319 20.358 1.456 0.416 0.459 0.294 0.270 20.248 1.166 0.347
CXCL9 0.517 0.347 0.303 20.318 1.352 0.428 1.004 0.317 0.007 0.239 1.770 0.831 20.487 0.274 0.187 21.149 0.174 0.403
CXCL10 1.094 0.372 0.013 0.197 1.991 0.718 0.944 0.421 0.072 20.068 1.956 0.620 0.150 0.388 0.921 20.784 1.084 0.100
XCR1 20.109 0.226 0.881 20.656 0.438 0.119 20.772 0.262 0.013 21.404 20.141 0.849 0.664 0.214 0.009 0.148 1.180 0.729
IL8 1.021 0.303 0.004 0.292 1.749 0.839 0.026 0.323 0.997 20.750 0.802 0.021 0.995 0.316 0.007 0.234 1.756 0.818
NR3C1 0.543 0.202 0.025 0.057 1.028 0.664 0.170 0.208 0.696 20.332 0.672 0.208 0.373 0.222 0.221 20.161 0.906 0.456
The table details results from pairwise comparisons between subject groups, including the mean differences in relative expression between subject groups, the
standard error (S.E.), p-value, 95% confidence interval (95% C.I.), and Cohen’s d. Significant pairwise comparisons (p#0.05) are highlighted in bold.
doi:10.1371/journal.pone.0091076.t003
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Discussion
Mood disorders are heterogeneous disorders that are diagnosed
when patients display a number of clinical characteristics. The
absence of a specific and objective diagnostic test has led to
relatively high rates of misdiagnosis for mood disorders, particu-
larly between MDD and BPD patients [12]. Recent reports have
revealed differences in cytokine gene expression between MDD
patients and controls, and BPD patients and controls [30,33]. This
follows a growing body of evidence linking immuno-inflammatory
processes with mood disorder pathophysiology and response to
mood disorder pharmacotherapies [25,35,37,39,45,46].
Here, we performed a small scale exploratory study which
aimed to identify the presence of transcriptional differences in the
inflammatory cytokine pathway between MDD, BPD and control
subjects in a ‘discovery cohort’, and to assess whether these
differences might act as biomarkers to differentiate between
subject groups in a ‘validation cohort’. Results from our discovery
cohort revealed 11 transcripts which differentiated between our
subject groups (see Table 3). The majority of these transcripts
coded for chemokines and chemokine receptors. However, two
notable exceptions include interleukin-8 (IL8) and the glucocor-
ticoid receptor (NRC31). Previous reports have found lowered
levels of IL-8 protein in the blood of MDD patients relative to
controls, and within the cerebrospinal fluid of suicide attempters
compared to controls [47–49]. In the current study we found that
lower transcription of IL8 distinguished both types of mood
disorder patient (MDD and BPD) from control subjects (see
Table 3). This may suggest that a common molecular pathway
impacting upon the transcription of IL8 could be involved in mood
disorder pathophysiology. We also found that MDD patients
exhibited decreased transcription of NRC31 relative to control
subjects (see Table 3). Lowered expression of NRC31 has
previously been reported both at the protein and transcriptional
level amongst MDD patients, and altered expression and
functionality of NRC31 has a recognized role in the pathophys-
iology of MDD [50]. However, neither IL8 nor NRC31 transcripts
significantly differentiated between subject groups in our valida-
tion cohort, which suggests that although they may be involved in
mood disorder pathophysiology, they were not reliable or specific
enough to be utilized as biomarkers in our study.
In contrast, higher transcription of CCL24 consistently differ-
entiated MDD patients from control and BPD subjects, and lower
transcription of CCR6 consistently differentiated MDD patients
from controls, in both our discovery and validation cohorts (see
Figure 1 and Figure 2). The transcription of these genes continued to
differentiate MDD patients from other subject groups even when
MDD blood was utilized from a different time point (see Results
section), corroborating the notion that transcriptional differences
in these genes likely relate to long-lasting state differences
associated with MDD, as opposed to more dynamic trait
differences. Furthermore, large effect sizes obtained for CCL24
and CCR6 (see Tables 3 and 4, and Results section) in both the
discovery and validation studies support the notion that transcrip-
tion of these genes could strongly differentiate MDD patients from
other subject groups, and thus might indeed be useful as
biomarkers.
Figure 1. A plot showing the adjusted relative expression of CCL24 (y-axis) in our control subjects, MDD subjects and BPD subjects
(x-axis) using data collected from our discovery cohort (shown in black), and our validation cohort (shown in red). Note the higher
transcription of CCL24 in the MDD subject group relative to the control and BPD subject groups.
doi:10.1371/journal.pone.0091076.g001
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Both CCL24 and CCR6 code for genes in the chemokine
cytokine family. The chemokines are small chemotactic cytokines
that facilitate the migration of immune cells (e.g. to a site of
infection) [48]. CCL24 codes for a chemokine which is chemotactic
for resting T lymphocytes, eosinophils, and to a lesser extent
neutrophils [51–52]. In contrast, CCR6 codes for a G-protein
coupled receptor present on immature dendritic cells, B cells and
memory T cells, and binds macrophage inflammatory protein 3
Figure 2. A plot showing the adjusted relative expression of CCR6 (y-axis) in our control subjects, MDD subjects and BPD subjects
(x-axis) using data collected from our discovery cohort (shown in black), and our validation cohort (shown in red). Note the lower
transcription of CCR6 in the MDD subject group relative to the control subject group.
doi:10.1371/journal.pone.0091076.g002
Table 4. A table detailing results from the one-tailed t-tests performed on our validation cohort, including t-values, degrees of
freedom (d.f.), p-values, and Cohen’s d.
Validation Cohort
Gene MDD v Control MDD v BPD BPD v Control Replication?
t d.f. p d t d.f. p d t d.f. p d
CCL24 2.394 23 0.013 0.998 2.674 23 0.007 1.115 - - - - Y
CCR4 21.218 23 0.118 0.508 - - - - - - - - N
CCR6 22.315 23 0.015 0.965 - - - - - - - - Y
CCR9 1.073 23 0.147 0.447 - - - - - - - - N
CXCL1 20.455 23 0.327 0.190 - - - - - - - - N
CXCL6 21.542 22 0.079 0.658 - - - - - - - - N
CXCL9 0.066 23 0.474 0.028 - - - - - - - - N
CXCL10 - - - - 0.214 22 0.416 0.091 - - - - N
XCR1 20.998 23 0.165 0.416 - - - - 20.879 18 0.391 0.414 N
IL8 - - - - 1.331 23 0.098 0.555 20.347 18 0.367 0.164 N
NR3C1 20.359 23 0.362 0.150 - - - - - - - - N
Significant pairwise comparisons (p#0.05) are highlighted in bold and indicated with a ‘Y’ under ‘Replication?’.
doi:10.1371/journal.pone.0091076.t004
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alpha [53]. Chemokines have previously been implicated as
potentially important cytokines in the pathophysiology of MDD
and higher levels of chemokine proteins have previously been
revealed amongst MDD patients relative to controls [26,48].
However, this is the first study to identify CCL24 and CCR6
transcripts as potential diagnostic biomarkers.
As well as gene transcription offering a more objective method
of clinical diagnosis, the fact that it is also a continuous measure
gives it certain advantages over currently utilized categorical
measures. For instance, continuous or dimensional diagnostic
measures are believed to be more stable over time, offer a better
measure of symptom severity, and be better predictors of
comorbidity and chronicity [54,55]. Subsequently, transcriptional
measures, such as those reported here, could be combined with
phenomenological or symptom dimension measures in future
diagnostic manuals to more sensitively capture clinically useful
information for MDD and BPD diagnosis.
Although results reported here are promising, there are five
main limitations to this study. Firstly, this study is an exploratory
study, utilizing relatively small sample sizes, and although we use
both a discovery and validation cohort, patients were obtained as
subsamples from the same studies, so it only offers a pseudo-
independent replication. Therefore replication studies are required
in a larger independent sample. Secondly, although we considered
the effects of different medications on gene expression profiles, all
of our patients were medicated. Based on our previous work on the
MDD patient sample used here, we can, with some confidence,
rule out the confounding effects of escitalopram treatment [39].
This was further supported by analyses on our MDD patients after
they were medication-free for two weeks (see Results section).
However, our BPD patient cohort were all treated with a variety of
medications, and although we could rule out the confounding
effects of each medication separately, we could not assess whether
common actions of different medications may have confounding
effects on gene transcription in our sample. Subsequently, future
studies in drug-free patients are required in order to validate the
transcript biomarkers identified in this study. Thirdly, although we
accounted for differences in age, sex, BMI, cardiovascular
problems and diabetes between our subject groups, we did not
have an extensive account of comorbidities or information on
smoking or alcohol drinking habits. Comorbid ailments such as
chronic pain, irritable bowel syndrome and arthritis are also
known to be more frequent amongst mood disorder patients and
may affect cytokine expression [56], subsequently a more extensive
list of comorbid disorders should be accounted for in future
studies. Fourth, time of day and seasonality have previously been
found to affect serum levels of cytokines, therefore this may act as a
possible confounding factor. Finally, without cell count informa-
tion we cannot determine the cell types in blood that may be
driving our observed transcript differences between subjects.
Despite its limitations, the current study utilizes well-character-
ized clinical samples, stringent quality control steps, normalization
protocols and statistical analyses. This study supports previous
reports of differences in the expression of IL8 and NR3C1 amongst
mood disorder patients. However, the lack of replication in our
validation cohort suggests that differences in the transcription of
these genes may not be reliable enough to be utilized as
biomarkers. Instead, this study emphasized the potential impor-
tance of chemokines as biomarkers, and specifically it identifies the
potential utility of CCL24 and CCR6 transcripts as novel
biomarkers differentiating MDD patients from control subjects
and BPD patients. Consequently, this study provides preliminary
evidence that CCL24 and CCR6 could be used in conjunction with
symptom measures to more accurately diagnose MDD from the
outset and differentiate MDD patients from non-depressed
subjects and BPD patients. Further replication studies are now
required in a larger medication-naı¨ve cohort to further validate
these findings.
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